+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Genome Editing Services Market: Focus on CRISPR, 2019-2030

  • ID: 4858623
  • Report
  • November 2019
  • 290 Pages
  • Roots Analysis
1 of 4
It is Worth Highlighting That, of all the Available Genome Manipulation Technologies, CRISPR is Currently Considered to be the Most Popular Tool

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • Blue Heron Biotech
  • Forevertek Biotechnology
  • JW Biotechnology
  • Oxford BioMedica
  • Synthego
  • MORE

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Market History

The 1970s witnessed the introduction of one of the most revolutionary advances in biotechnology, when Hamilton Smith (a molecular biologist at Johns Hopkins University School of Medicine) purified the first site-specific restriction enzyme, called Hind II. This development enabled the scientific community to devise the means to manipulate living organisms at the genetic level, opening up a plethora of opportunities in fundamental and applied life science research.

Soon after, in the 1980s, the US FDA approved the world’s first genetically engineered drug, which was human insulin marketed under the brand name HUMULIN®. Genetic engineering and genome editing concepts have evolved significantly over the last two decades, with the development of a variety of versatile DNA modulation technologies including zinc finger nucleases, transcription activator-like effector-based nucleases (TALENs), and the clustered regularly interspaced short palindromic repeats (CRISPR). These developments have enabled medical researchers to perform an array of gene/cell line engineering experiments, including gene knockdowns, gene overexpressions and single base editing, for a variety of R&D applications.

It is worth highlighting that, of all the available genome manipulation technologies, CRISPR is currently considered to be the most popular tool, owing to its fast, accurate, and cost-effective approach. In fact, in 2018, scientists Emmanuelle Charpentier, Jennifer Doudna, and Virginijus Siksnys were felicitated for their pioneering efforts on the CRISPR-Cas9 technology, with the prestigious Kavli Prize in Nanoscience.

Current Insights

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

  • A detailed assessment of the current market landscape, featuring an elaborate list of over 80 companies that offer CRISPR-based genome editing services, and analyses based on a number of relevant parameters, such as type of gRNA service, availability of gRNA format, type of endonuclease, type of Cas9 endonuclease format, type of cell line engineering offering, type of cell line, type of animal model generation offering, availability of CRISPR libraries and important service provider details (year of establishment, company size and location of headquarters).  
  • An insightful 2X2 representation, highlighting the competitiveness of various CRISPR-based genome editing service providers captured in our database (segregated across various peer groups based on company size), taking into consideration the supplier power and the specific genome editing capabilities (which include gRNA service(s), endonuclease service(s), cell line engineering service(s), animal model generation service(s) and availability of CRISPR library(s)) of different companies.
  • Elaborate profiles of key players (shortlisted based on strength of service portfolio), featuring a brief overview of the company, its financial performance (if available), a detailed description of its genome editing service offerings, recent developments and an informed future outlook.
  • An in-depth analysis of over 10,000 patents related to CRISPR technology that have been filed/granted, since 2006, highlighting key trends associated with these patents, across type of patent, publication year and application year, regional applicability, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed/granted), patent benchmarking and valuation.  
  • A detailed analysis of close to 2,000 grants that have been awarded to support research projects related to CRISPR, between 2015 and 2019 (till September), highlighting important parameters, such as year of award, amount awarded, administring institute center, support period, funding mechanism, type of grant application, grant activity, type of recipient organization, regional distribution of recipient organization, prominent project leaders and emerging focus areas. It also features a detailed multivariate grant attractiveness analysis based on the amount awarded, support period, grant type and funding mechanism.
  • A discussion on the advanced technologies and systems that have been developed to improve CRISPR-related processes. It includes a list of companies that have developed such innovative technology platforms, along with details on a number of relevant parameters, such as year of establishment, company size, core expertise, location of headquarters and important technology specifications (including technology name, focus area and key features). In addition, it includes short profiles of key technology providers. Further, the chapter highlights a list of companies that offer CRISPR kits and CRISPR design tools.
  • An analysis highlighting potential strategic partners, segregated based on likelihood of entering into collaboration with CRISPR-based genome editing services providers. The analysis takes into consideration multiple relevant parameters, such as type of therapy, pipeline strength, pipeline maturity, company strength and therapeutic area.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world). To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the CRISPR-based genome editing services market in the short to mid-term, and long term.

Chapter 3 provides a brief overview, history and applications of genome editing. It includes detailed discussion on the different types of currently available genome editing techniques. In addition, the chapter provides details of CRISPR technology along with the information on role of CRISPR/Cas in bacterial adaptive immunity, key CRISPR/Cas systems and components of CRISPR/Cas system. Further, it includes details on protocol associated with CRISPR-based genome editing, applications of CRISPR and associated key challenges and future perspectives.

Chapter 4 provides a comprehensive view on the current landscape of CRISPR-based genome editing service providers. It includes information related to over 80 companies that claim to offer CRISPR-based genome editing services, featuring an in-depth analyses of the players based on their service offering including gRNA service (gRNA design and gRNA construction), availability of gRNA format (plasmid, lentivirus, AAV, adenovirus and others), type of endonuclease (Cas9, Cpf1 and others), availability of Cas9 format (mRNA, plasmid, lentivirus, AAV, protein and others), type of cell line engineering offering (knockout, knockin, tagging/reporters and others), type of cell line (stem cell lines, human cell lines, other mammalian cell lines and others (microbial, insects and others)), type of animal model generation offering (mice/mouse, rat, zebrafish, C.elegans and others), availability of CRISPR libraries and important service provider details (year of establishment, headquarter location(s), company size).

Chapter 5 features a comprehensive 2X2 analysis offering a comparative summary of all the CRISPR-based genome editing service providers that we came across during our research. The analysis compares the aforementioned companies within three peer-groups, established based on size of employee base (small-sized (1-200 employees), mid-sized (>201-1,000 employees) and large (>1,000 employees)). The companies were compared based on their genome editing capabilities (including gRNA service(s), endonuclease service(s), cell line service(s), animal model generation service(s), CRISPR library(s)) and supplier power.

Chapter 6 features profiles of CRISPR-based genome editing service providers (shortlisted based on strength of service portfolio). Each profile features an overview of the company, its financial performance (if available), brief details of genome editing service portfolio, recent developments and an informed future outlook.

Chapter 7 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed since 2006 related to CRISPR technology. The analysis also highlights the key trends associated with these patents, including type of patent (granted patent, patent application and others), publication year and application year, geography (North America, Europe, Asia-Pacific and Rest of the World), CPC symbols (Top 15 CPC symbols), key focus areas, leading industry/non-industry players, patent benchmarking analysis and patent valuation analysis.

Chapter 8 provides information on close to 2,200 grants that were awarded to research institutes engaged in projects related to CRISPR technology, between 2015 and 2019 (till September). The analysis also highlights important parameters associated with grants, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, grant activity, type of recipient organization, regional distribution of recipient organization, prominent project leaders and emerging focus areas. It also features a detailed multivariate grant attractiveness analysis based on the amount awarded, support period, grant type and funding mechanism.

Chapter 9 provides details of innovative technology platforms (such as integration of delivery platforms, enzyme technologies, protein technologies and others with the fundamental CRISPR technology) to improve CRISPR processes. It includes the list of companies that are focused on the development of these technologies along with details on a number of parameters, such as year of establishment, headquarter location(s), company size, company expertise and technology details (name, focus and key features). In addition, it includes tabulated profiles of key technology providers, with details on company overview, funding and collaboration instances. Further, the chapter highlights a list of companies that offer CRISPR design tools and kits.

Chapter 10 features an insightful analysis, highlighting potential strategic partners (for instance, drug developers) for CRISPR-based genome editing service providers, based on multiple parameters, such as type of therapy, pipeline strength, pipeline maturity, company strength and therapeutic area. The analysis aims to provide the necessary inputs to the stakeholders, enabling them to make the right decisions to conduct research work with the help the appropriate partner entities.

Chapter 11 features a comprehensive market forecast, highlighting the future potential of CRISPR-based genome editing services market till 2030. The projected opportunity has been further analyzed to develop a better perspective related to its distribution across [A] type of services (gRNA construction, cell line engineering and animal model generation), [B] type of cell line (mammalian, microbial, insect and others) and [C] different global regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 12 provides a discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis, that highlights the relative impact of each SWOT parameter on the overall CRISPR-based genome editing services market.

Chapter 13 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the CRISPR technology domain.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 15 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • Blue Heron Biotech
  • Forevertek Biotechnology
  • JW Biotechnology
  • Oxford BioMedica
  • Synthego
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Context and Background
3.2. Overview of Genome Editing
3.3. History of Genome Editing
3.4. Applications of Genome Editing
3.5. Genome Editing Techniques
 
3.5.1. Mutagenesis
3.5.2 Conventional Homologous Recombination
3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination
3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)
 
3.5.5. Protein-based Nuclease Systems
3.5.5.1. Meganucleases
3.5.5.2. Zinc Finger Nucleases
3.5.5.3. Transcription Activator-like Effector Nucleases
 
3.5.6. DNA Guided Systems
3.5.6.1. Peptide Nucleic Acids
3.5.6.2. Triplex Forming Oligonucleotides
3.5.6.3. Structure Guided Endonucleases
 
3.5.7. RNA Guided Systems
3.5.7.1. CRISPR-Cas9
3.5.7.2. Targetrons
 
3.6. CRISPR-based Genome Editing
3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria
3.6.2. Key CRISPR-Cas Systems
3.6.3. Components of CRISPR-Cas System
3.6.4. Protocol for CRISPR-based Genome Editing
 
3.7. Applications of CRISPR
3.7.1. Development of Therapeutic Interventions
3.7.2. Augmentation of Artificial Fertilization Techniques
3.7.3. Development of Genetically Modified Organisms
3.7.4. Production of Biofuels
3.7.5. Other Bioengineering Applications
 
3.8. Key Challenges and Future Perspectives
 
4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape
4.2.3. Analysis by Type of Service Offering
4.2.4. Analysis by Type of gRNA Format
4.2.5. Analysis by Type of Endonuclease
4.2.6. Analysis by Type of Cas9 Format
4.2.7. Analysis by Type of Cell Line Engineering Offering
4.2.8. Analysis by Type of Animal Model Generation Offering
4.2.9. Analysis by Availability of CRISPR Libraries
4.2.10. Analysis by Year of Establishment
4.2.11. Analysis by Company Size
4.2.12. Analysis by Geographical Location
4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters
 
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape
5.4.1. Small-sized Companies
5.4.2. Mid-sized Companies
5.4.3. Large Companies
 
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Applied StemCell
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Recent Developments and Future Outlook
 
6.3. BioCat
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Recent Developments and Future Outlook
 
6.4. Biotools
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Recent Developments and Future Outlook
 
6.5. Charles River Laboratories
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Recent Developments and Future Outlook
 
6.6. Cobo Scientific
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Recent Developments and Future Outlook
 
6.7. Creative Biogene
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Recent Developments and Future Outlook
 
6.8. Cyagen Biosciences
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Recent Developments and Future Outlook
 
6.9. GeneCopoeia
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Recent Developments and Future Outlook
 
6.10. Horizon Discovery
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Service Portfolio
6.10.4. Recent Developments and Future Outlook
 
6.11. NemaMetrix
6.11.1. Company Overview
6.11.2. Service Portfolio
6.11.3. Recent Developments and Future Outlook
 
6.12. Synbio Technologies
6.12.1. Company Overview
6.12.2. Service Portfolio
6.12.3. Recent Developments and Future Outlook
 
6.13. Thermo Fisher Scientific
6.13.1. Company Overview
6.13.2. Financial Information
6.13.3. Service Portfolio
6.13.4. Recent Developments and Future Outlook
 
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
 
7.3. CRISPR-based Genome Editing: Patent Analysis
7.3.1. Analysis by Application Year and Publication Year
7.3.2. Analysis by Geography
7.3.3. Analysis by CPC Symbols
7.3.4. Emerging Focus Areas
7.3.5. Leading Players: Analysis by Number of Patents
 
7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Patent Valuation Analysis
 
8. ACADEMIC GRANT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Grants Awarded by the National Institutes of Health for CRISPR-based
8.3.1. Year-wise Trend of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institutes
8.3.4. Analysis by Support Period
8.3.5. Analysis by Funding Mechanism
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Grant Activity
8.3.8. Analysis by Recipient Organization
8.3.9. Regional Distribution of Grant Recipient Organization
8.3.10. Prominent Project Leaders: Analysis by Number of Grants
8.3.11. Emerging Focus Areas
8.3.12. Grant Attractiveness Analysis
 
9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES/SYSTEMS AND TOOLS
9.1. Chapter Overview
9.2. CRISPR-based Technology Providers
9.2.1. Analysis by Year of Establishment and Company Size
9.2.2. Analysis by Geographical Location and Company Expertise
9.2.3. Analysis by Focus Area
9.2.4. Key Technology Providers: Company Snapshots
9.2.4.1. APSIS Therapeutics
9.2.4.2. Beam Therapeutics
9.2.4.3. CRISPR Therapeutics
9.2.4.4. Editas Medicine
9.2.4.5. Intellia Therapeutics
9.2.4.6. Jenthera Therapeutics
9.2.4.7. KSQ Therapeutics
9.2.4.8. Locus Biosciences
9.2.4.9. Refuge Biotechnologies
9.2.4.10. Repare Therapeutics
9.2.4.11. SNIPR BIOME
9.2.5. Key Technology Providers: Summary of Venture Capital Investments
9.3. List of CRISPR Kit Providers
9.4. List of CRISPR Design Tool Providers
 
10. POTENTIAL STRATEGIC PARTNERS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Potential Strategic Partners for Genome Editing Service Providers
10.3.1. Key Industry Partners
10.3.1.1. Most Likely Partners
10.3.1.2. Likely Partners
10.3.1.3. Less Likely Partners
 
10.3.2. Key Non-Industry/Academic Partners
10.3.2.1. Most Likely Partners
10.3.2.2. Likely Partners
10.3.2.3. Less Likely Partners
 
11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall CRISPR-based Genome Editing Services Market, 2019-2030
11.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-2030
11.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-2030
11.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-2030
11.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-2030
11.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-2030
 
11.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-2030
11.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-2030
11.5.1.1. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, 2019-2030
11.5.1.2. CRISPR-based Genome Editing Services Market for gRNA Construction in Europe, 2019-2030
11.5.1.3. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, 2019-2030
11.5.1.4. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, 2019-2030
 
11.6.1. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-2030
11.6.1.1. CRISPR-based Genome Editing Services Market for Cell Line Engineering in North America, 2019-2030
11.6.1.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Europe, 2019-2030
11.6.1.3. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Asia Pacific, 2019-2030
11.6.1.4.
 
11.7.1. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-2030
11.7.1.1. CRISPR-based Genome Editing Services Market for Animal Model Generation in North America, 2019-2030
11.7.1.2. CRISPR-based Genome Editing Services Market for Animal Model Generation in Europe, 2019-2030
11.7.1.3. CRISPR-based Genome Editing Services Market for Animal Model Generation in Asia Pacific, 2019-2030
11.7.1.4. CRISPR-based Genome Editing Services Market for Animal Model Generation in Rest of the World, 2019-2030
 
11.8. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-2030
11.8.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-2030
11.8.1.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in North America, 2019-2030
11.8.1.2. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Europe, 2019-2030
11.8.1.3. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Asia Pacific, 2019-2030
11.8.1.4. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Rest of the World, 2019-2030
 
11.9.1. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-2030
11.9.1.1. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in North America, 2019-2030
11.9.1.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Europe, 2019-2030
11.9.1.3. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Asia Pacific, 2019-2030
11.9.1.4. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Rest of the World, 2019-2030
 
11.10.1. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030
11.10.1.1. CRISPR-based Genome Editing Services Market for Other Cell Lines in North America, 2019-2030
11.10.1.2. CRISPR-based Genome Editing Services Market for Other Cell Lines in Europe, 2019-2030
11.10.1.3. CRISPR-based Genome Editing Services Market for Other Cell Lines in Asia Pacific, 2019-2030
11.10.1.4. CRISPR-based Genome Editing Services Market for Other Cell Lines in Rest of the World, 2019-2030
 
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. SWOT Analysis
12.2.1. Strengths
12.2.2. Weaknesses
12.2.3. Opportunities
12.2.4. Threats
12.2.5. Concluding Remarks
 
13. EXECUTIVE INSIGHTS
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 302 Military Hospital of China
  • 4D Molecular Therapeutics
  • AAVogen
  • AB SCIEX
  • AbbVie
  • AbCheck
  • AbClon
  • Abeona Therapeutics
  • ACROBiosystems
  • Actus Therapeutics
  • Acucela
  • Adaptimmune Therapeutics
  • Adicet Bio
  • Advantagene
  • Advaxis
  • Adverum Biotechnologies
  • Adverum Biotechnologies
  • Aeon Therapeutics
  • Affiliated Hospital to Academy of Military Medical Sciences
  • Agency for Science, Technology and Research (A*STAR)
  • AgenTus Therapeutics
  • Agilent Technologies
  • Agilis Biotherapeutics
  • Akouos
  • Albert Einstein College of Medicine
  • Aldevron
  • Alex's Lemonade Stand Foundation
  • Allergan
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • AlphaVax
  • ALSTEM
  • Altor Bioscience
  • American Gene Technologies
  • Amgen
  • Amicus Therapeutics
  • AMS Biotechnology
  • Anaeropharma Science
  • Analytical Biological Services
  • Anchiano Therapeutics
  • AnGes
  • Angionetics
  • Anhui Provincial Hospital
  • Animalab
  • Antagene
  • Antibody Design Labs
  • Apic Bio
  • Applied Biological Materials (abm)
  • Applied Genetic Technologies (AGTC)
  • Applied StemCell
  • APSIS Therapeutics
  • ARBELE
  • Arbor Biosciences
  • Arthrogen
  • Aruvant Sciences
  • AskBio
  • Astellas Pharma
  • Atara Biotherapeutics
  • Atossa Genetics
  • Atreca
  • ATUM
  • Auburn University
  • Audentes Therapeutics
  • AuraGen
  • Aurora Biopharma
  • Autolus
  • Avacta
  • Avectas
  • AveXis
  • AVROBIO
  • Axol Bioscience
  • Axovant Gene Therapies
  • Bamboo Therapeutics
  • Baxter
  • Bayer
  • Baylor College of Medicine
  • Beam Therapeutics
  • Beijing Biohealthcare Biotechnology
  • Beijing Cancer Hospital
  • Beijing Doing Biomedical
  • Beijing Immunochina Medical Science & Technology
  • Beijing Lu Daopei Hospital
  • Beijing Mario Biotech
  • Beijing Sanbo Brain Hospital
  • Beijing Sanwater Biological Technology
  • Bellicum Pharmaceuticals
  • Benchling
  • Berlin Institute of Health
  • Bill & Melinda Gates Foundation
  • BioAtla
  • BioCat
  • Bioceltech Therapeutics
  • BioChain
  • Biocodon Technologies
  • Biocytogen
  • Biogen
  • BioInvent
  • Biolegio
  • Biologics International
  • BioMarin
  • Bioneer
  • Bionic Sight
  • BioNTech
  • Biotools
  • Bioverativ
  • Blue Heron Biotech
  • bluebird bio
  • B-MoGen Biotechnologies
  • Boehringer Ingelheim
  • Boston Children's Hospital
  • Bristol-Myers Squibb
  • Broad Institute
  • Brown University
  • Butterfly sciences
  • California Institute for Regenerative Medicine
  • California Institute of Technology
  • Calimmune
  • Cambridge Bioscience
  • Cancer Research UK
  • Canopy BioSciences
  • Captain T Cell
  • Cardiogen Sciences
  • Caribou Biosciences
  • Carina Biotech
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Cartherics
  • Case Comprehensive Cancer Center
  • CASPR Biotech
  • Castle Creek Pharma
  • Celenex
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Medica
  • Cellecta
  • Cellectis
  • CellGenTech
  • CellSystems
  • Cellular Biomedicine Group
  • Cellular Therapeutics
  • Celsion
  • Celvab
  • Celyad
  • Center for Applied Medical Research (CIMA)
  • Center for Cell and Gene Therapy
  • Changhai Hospital
  • Changzheng Hospital
  • Charles River Laboratories
  • Chatham Therapeutics
  • Chiba University
  • Children's Hospital and Health System Foundation
  • Children's Hospital of Fudan University
  • Children's Hospital of Philadelphia
  • Children's Mercy Kansas City
  • China Immunotech
  • China Meitan General Hospital
  • Chinese Academy of Sciences
  • Chinese PLA General Hospital
  • City of Hope National Medical Center
  • Cobo Scientific
  • Coderegenesis
  • Cold Genesys
  • CombiGene
  • Copernicus Therapeutics
  • Cosmo Bio
  • Creative Bioarray
  • Creative Biogene
  • CRISPR Therapeutics
  • CrownBio
  • CSL Behring
  • Cyagen
  • Cynvec
  • Cytovant Sciences
  • Daiichi Sankyo
  • Dana-Farber Cancer Institute
  • Defense Advanced Research Projects Agency (DARPA)
  • DefiniGEN
  • Desktop Genetics
  • Dimension Therapeutics
  • Discovery Genomics
  • DNAlite Therapeutics
  • DNAtrix
  • Dongguan People's Hospital
  • Dow AgroSciences
  • Duke University Medical Center
  • Duke-NUS Medical School
  • EdiGene
  • Editas Medicine
  • eGenesis Bio
  • Ehime University
  • Eli Lilly
  • Endocyte
  • Endsulin
  • Enochian BioSciences
  • Entos Pharmaceuticals
  • Epeius Biotechnologies
  • Errant Gene Therapeutics
  • ERS Genomics
  • Esteve
  • Eureka Therapeutics
  • Eutilex
  • Exonics Therapeutics
  • ExpressCells
  • Expression Therapeutics
  • EXUMA Biotechnology
  • Eyevensys
  • F1 Oncology
  • Fate Therapeutics
  • Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology
  • Fibrocell
  • First Affiliated Hospital of Chengdu Medical College
  • First Affiliated Hospital of Guangdong Pharmaceutical University
  • First Affiliated Hospital of Zhejiang University
  • First People's Hospital of Foshan
  • First People's Hospital of Yunnan
  • FIT Biotech
  • Five Prime Therapeutics
  • FKD Therapies
  • Flexion Therapeutics
  • Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  • Forevertek Biotechnology
  • Formula Pharmaceuticals
  • Fosun Pharma
  • Fred Hutchinson Cancer Research Center
  • Freeline Therapeutics
  • Fuda Cancer Hospital
  • Fudan University
  • Fujian Cancer Hospital
  • Fujian Medical University
  • Fujita Health University
  • Fulcrum Therapeutics
  • Gadeta
  • GEG Tech
  • Gemini Therapeutics
  • Genable Technologies
  • GenAhead Bio
  • GeneCopoeia
  • GeneCure Biotechnologies
  • GenEdit
  • Genelux
  • Genentech
  • GeneOne Life Science
  • GenePharma
  • GeneQuine Biotherapeutics
  • Generation Bio
  • Genethon
  • Genetics Research
  • GENEWIZ
  • Genexine
  • Genmab
  • genOway
  • Genprex
  • GenScript
  • GenSight Biologics
  • Genus Oncology
  • GenVec
  • German Cancer Research Center
  • GigaGen
  • GlaxoSmithKline
  • Glycostem
  • Gracell Biotechnologies
  • Gradalis
  • Green Cross Cell
  • GSK
  • Guangdong General Hospital
  • Guangdong Xiangxue Precision Medical Technology
  • Guangdong Zhaotai InVivo Biomedicine
  • Guangzhou Anjie Biomedical Technology
  • Guangzhou Doublle Bioproducts
  • Guangzhou Eighth People's Hospital
  • Guangzhou FineImmune Biotechnology
  • Guangzhou First People's Hospital
  • Guangzhou Yi Yan Biological Technology
  • Gynecologic Oncology Group Foundation
  • Gyroscope Therapeutics
  • Hanyang University
  • Harvard College
  • Harvard University
  • Hebei Senlang Biotechnology
  • Hebei Yanda Ludaopei Hospital
  • Hefei Binhu Hospital
  • Heidelberg University
  • Helix BioPharma
  • Helixmith
  • Hemera Biosciences
  • Henan Cancer Hospital
  • Henan Hualong Biotechnology
  • Herantis Pharma
  • Histogenics
  • Holostem Terapie Avanzate
  • Homology Medicines
  • HORAMA
  • Horizon Discovery
  • Hrain Biotechnology
  • Huaian First People's Hospital
  • Huazhong Agricultural University
  • Huazhong University of Science and Technology
  • Human Stem Cells Institute
  • Hunan Provincial People's Hospital
  • Hunan Yongren Medical Innovation
  • Hunan Zhaotai Yongren Biotech
  • Hunterian Medicine
  • Icahn School of Medicine at Mount Sinai
  • iCAR Bio Therapeutics
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • Icell Kealex Therapeutics
  • ICON
  • IDeal Genetics
  • i-DNA Biotechnology
  • ILPEN Scientific Equipment & Supplies
  • Immatics
  • Immune Therapeutics
  • Immunocore
  • ImmunoGenes
  • Immusoft
  • ingenious targeting laboratory
  • Innovative Cellular Therapeutics
  • Inotek Pharmaceuticals
  • Inovio Pharmaceuticals
  • Inscripta
  • Institute of Hematology & Blood Diseases Hospital
  • Integrated DNA Technologies
  • Intellia Therapeutics
  • Intrexon
  • Invectys
  • Iowa State University
  • IVERIC bio
  • IWK Health Centre is affiliated to Dalhousie University, to be added as separate entries
  • Janssen Pharmaceuticals
  • Jennerex Biotherapeutics
  • Jenthera Therapeutics
  • Jichi Medical University
  • Jingzhou Central Hospital
  • Johns Hopkins Kimmel Cancer Center
  • Jonsson Comprehensive Cancer Center
  • Juno Therapeutics
  • Juventas Therapeutics
  • JW Biotechnology
  • KAEDI
  • King's College London
  • Kite Pharma
  • Kolon TissueGene
  • Krystal Biotech
  • KSQ Therapeutics
  • Labomics
  • Lacerta Therapeutics
  • Leiden University Medical Center
  • Leland Stanford Junior University
  • Leucid Bio
  • LifeEDIT
  • Ligandal
  • Liminatus Pharma
  • Lion TCR
  • Living Pharma
  • Locus Biosciences
  • LogicBio Therapeutics
  • Lokon Pharma
  • Lonza
  • Loop Genomics
  • Loyola University
  • LubioScience
  • Lucigen
  • Ludwig Cancer Research
  • Lysogene
  • MabVax Therapeutics
  • Macrogen
  • Mammoth Biosciences
  • Marino Biotechnology
  • Marsala Biotech
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • MaxCyte
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Medical College of Wisconsin
  • Medigene
  • MedImmune
  • Medisix Therapeutics
  • MeiraGTx
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Mesoblast
  • Microsynth
  • Mie University Hospital
  • Milo Biotechnology
  • Miltenyi Biotec
  • Minerva Biotechnologies
  • MingJu Therapeutics
  • Mirimus
  • Moffitt Cancer Center
  • MolMed
  • Momotaro-Gene
  • Monsanto
  • MultiVir
  • Mustang Bio
  • Myonexus Therapeutics
  • Nagoya University
  • Nanfang Hospital of Southern Medical University
  • Nanjing Children's Hospital
  • Nanjing Legend Biotech
  • NanoCor Therapeutics
  • Nanogenics
  • Nanosens Innovations
  • National Cancer Institute
  • National Eye Institute
  • National Heart, Lung, and Blood Institute
  • National Human Genome Research Institute
  • National Institute of Aging
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institute of Child Health and Human Development
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of General Medical Sciences
  • National Institute of Mental Health
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Drug Abuse
  • National Institutes of Health
  • Nationwide Children's Hospital
  • Navy General Hospital
  • Ncardia
  • NemaMetrix
  • Neuracle Genetics
  • Neuralgene
  • Neurocrine Biosciences
  • Neurogene
  • New England Biolabs
  • Nightstar Therapeutics
  • Ningbo Cancer Hospital
  • NIPRO
  • NMI TT Pharmaservices
  • Noahgen
  • Nohla Therapeutics
  • Noile-Immune Biotech
  • Novartis
  • NTrans Technologies
  • Obsidian Therapeutics
  • Ocugen
  • omicX
  • Oncolys BioPharma
  • Oncos Therapeutics
  • OncoSec Medical
  • Orbit Biomedical
  • ORCA Therapeutics
  • Orchard Therapeutics
  • OriGene Technologies
  • Ottawa Hospital Research Institute
  • Oxford BioMedica
  • Oxford Genetics
  • OZ Biosciences
  • Pacific Biosciences
  • Parker Institute for Cancer Immunotherapy
  • Passage Bio
  • Pattern BioSciences
  • Peking University
  • PeproMene Bio
  • PeriphaGen
  • PersonGen BioTherapeutics
  • Peter MacCallum Cancer Centre
  • Pfizer
  • PHENOMIN-ICS
  • Pinze Lifetechnology
  • Pioneer Hi-Bred International
  • PlasmaTech Biopharmaceuticals
  • PNA Bio
  • PolyGene
  • Poseida Therapeutics
  • Precigen
  • Precision BioSciences
  • Precision Genome Engineering
  • Precision Virologics
  • Prevail Therapeutics
  • Promab Biotechnologies
  • Promega
  • Promethera Biosciences
  • Protheragen
  • PsiOxus Therapeutics
  • PTC Therapeutics
  • Purdue University
  • Qingdao Central Hospital
  • Quethera
  • Recombinetics
  • Refuge Biotechnologies
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • RenJi Hospital
  • Renova Therapeutics
  • Rentschler Biopharma
  • Repare Therapeutics
  • ReproCELL
  • RetroSense Therapeutics
  • Reyon Pharmaceutical
  • Roche
  • Rocket Pharmaceuticals
  • Rockland Immunochemicals
  • Roger Williams Medical Center
  • Roswell Park Cancer Institute
  • Royal Adelaide Hospital Cancer Centre
  • Ruijin Hospital
  • Ryboquin
  • San Raffaele Hospital
  • Sanct
  • Sangamo Therapeutics
  • Sanofi
  • Sarepta Therapeutics
  • SCANBUR
  • Scancell
  • SciGenom Labs
  • Scotia Biologics
  • Seattle Children's Hospital
  • Seattle Children's Research Institute
  • Seattle Genetics
  • Second Affiliated Hospital of Guangzhou Medical University
  • Second Affiliated Hospital of Xi'an Jiaotong University
  • Second Military Medical University
  • Second Xiangya Hospital of Central South University
  • Selecta Biosciences
  • Servier
  • Shanghai Bioray Laboratory
  • Shanghai Changzheng Hospital
  • Shanghai Children's Medical Center
  • Shanghai East Hospital
  • Shanghai GeneChem
  • Shanghai General Hospital
  • Shanghai International Medical Center
  • Shanghai Jiao Tong University School of Medicine
  • Shanghai Longyao Biotechnology
  • Shanghai Public Health Clinical Center
  • Shanghai Sinobioway Sunterra Biotech
  • Shanghai Sixth People's Hospital
  • Shanghai Sunway Biotech
  • Shanghai Tenth People's Hospital
  • Shanghai Tong Ren Hospital
  • Shanghai Tongji Hospital
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Sheba Medical Center
  • Shenzhen BinDeBio
  • Shenzhen Geno-immune Medical Institute
  • Shenzhen Institute for Innovation and Translational Medicine
  • Shenzhen Second People's Hospital
  • Sherlock Biosciences
  • Shionogi
  • Shire (acquired by Takeda Pharmaceutical)
  • Sibiono GeneTech
  • Sichuan University
  • Sidney Kimmel Cancer Center
  • Sigma Aldrich
  • SillaJen
  • Sinobioway Cell Therapy
  • SNIPR BIOME
  • Solid Biosciences
  • Sorrento Therapeutics
  • Southern Medical University
  • Southwest Hospital
  • Spanish National Centre for Biotechnology
  • Spark Therapeutics
  • Spindle Biotech
  • SR-TIGET
  • St. Jude Children's Research Hospital
  • Stanford University
  • STEMCELL Technologies
  • Stony Brook University
  • StrideBio
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • SunyBiotech
  • Super-T Cell Cancer Company
  • Syd Labs
  • Symvivo
  • Synbio Technologies
  • Syngenta Participations
  • Synthego
  • System Biosciences
  • Taconic Biosciences
  • Tactiva Therapeutics
  • Takara Bio
  • Takeda Pharmaceutical
  • Targazyme
  • Targovax
  • Tasly Biopharmaceuticals
  • Taxus Cardium Pharmaceuticals
  • TC BioPharm
  • TCR2 Therapeutics
  • TCRCure Biopharma
  • tebu-bio
  • Tenaya Therapeutics
  • Tessa Therapeutics
  • Texas Children's Hospital
  • The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
  • The Bambino Gesu` Children's Hospital
  • The Beijing Pregene Science and Technology
  • The Cancer Hospital of Yunnan
  • The First Affiliated Hospital of Anhui Medical University
  • The First Affiliated Hospital of Chongqing Medical University
  • The First Affiliated Hospital of Harbin Medical University
  • The First Affiliated Hospital of Jinan University
  • The First Affiliated Hospital of Soochow University
  • The First Affiliated Hospital of Wenzhou Medical University
  • The First Affiliated Hospital of Zhengzhou University
  • The First Affiliated Hospital with Nanjing Medical University
  • The First Hospital of Jilin University
  • The First People's Hospital of Hefei
  • The First People's Hospital of Yuhang District
  • The General Hospital of Western Theater Command
  • The Methodist Hospital System
  • The Netherlands Cancer Institute
  • The Pregene (ShenZhen) Biotechnology
  • The Second Affiliated Hospital of Hainan Medical University
  • The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  • The Second Hospital of Anhui Medical University
  • The Second Hospital of Hebei Medical University
  • The Second Hospital of Nanjing Medical University
  • The Second Military Medical University
  • The Sixth Affiliated Hospital of Wenzhou Medical University
  • The Third Affiliated Hospital of Southern Medical University
  • The University of Chicago
  • The Wistar Institute
  • TheraBiologics
  • THERAVECTYS
  • Thermo Fisher Scientific
  • Third Affiliated Hospital
  • Third Military Medical University
  • Thomas Jefferson University
  • THP Medical Products
  • Tianjin Medical University Cancer Institute and Hospital
  • Tianjin Mycure Medical Technology
  • Tianjin People's Hospital
  • TILT Therapeutics
  • Timmune Biotech
  • Tmunity Therapeutics
  • TNK Therapeutics, subsidiary of Sorrento Therapeutics
  • Tocagen
  • Tongji Hospital
  • Tongji Medical College
  • Tongji University School of Medicine
  • Toni Stephenson Lymphoma Center
  • ToolGen
  • Transgene
  • Transposagen Biopharmaceuticals
  • Trilink Biotechnologies
  • TxCell
  • UC Davis Medical Center
  • UK Cystic Fibrosis Gene Therapy Consortium
  • Ultragenyx Pharmaceutical
  • UNC Lineberger Comprehensive Cancer Center
  • Union Stem Cell & Gene Engineering
  • uniQure Biopharma
  • United States Department of Defense
  • Universal Cells
  • Universitat Autònoma de Barcelona
  • University Health Network
  • University Hospital Heidelberg
  • University Medical Center Utrecht
  • University of Bergen
  • University of California
  • University of Cologne
  • University of Connecticut
  • University of Florida
  • University of Georgia
  • University of Massachusetts Medical School
  • University of Oxford
  • University of Pennsylvania
  • University of Southern California
  • University of Technology
  • University of Texas MD Anderson Cancer Center
  • University of Zurich
  • Unum Therapeutics
  • Uppsala University
  • Urovant Sciences
  • UT Southwestern Medical Center
  • V Foundation
  • ValueAct Capital Management
  • VBL Therapeutics
  • VCN Biosciences
  • Vector Neurosciences
  • VectorBuilder
  • Velaz
  • Vertex Pharmaceuticals
  • Verve Therapeutics
  • Vessl™
  • Vigene Biosciences
  • Virttu Biologics
  • Vivet Therapeutics
  • Vivo Bio Tech
  • Vor Biopharma
  • Voyager Therapeutics
  • Washington University
  • Weill Cornell Medical College
  • Welgen
  • West China Hospital
  • Wuhan Sian Medical Technology
  • Wuhan Union Hospital
  • WuXi AppTec
  • Wyvern Pharmaceuticals
  • Xiangxue Life Sciences
  • Xiangxue Pharmaceutical
  • Xiangyang Central Hospital
  • Xijing Hospital
  • Xinqiao Hospital
  • XpressBio
  • Xuanwu Hospital
  • Xuzhou Medical University
  • XyloCor Therapeutics
  • Yake Biotechnology
  • Yale University
  • Yamaguchi University Graduate School of Medicine
  • Yan'an Affiliated Hospital of Kunming Medical University
  • Yuanyi Biotechnology
  • ZeClinics
  • Zelluna Immunotherapy
  • ZenBio
  • Zhejiang University
  • Zhongshan Hospital
  • Zhujiang Hospital of Southern Medical University
  • Ziopharm Oncology
Note: Product cover images may vary from those shown
5 of 4

 

 

Loading
LOADING...

Adroll
adroll